Skip to main content

Table 1 Study subjects for the assessment of IL-22 and IL-22BP in the blood

From: Interleukin-22 is increased in multiple sclerosis patients and targets astrocytes

Category N = 141 Male/female ratio Age at blood draw (years)a EDSSa Disease duration (years)a Last relapse (months)a
Clinically active MS patients 26 7/19 31.5 ± 10.0 2.00 ± 1.00 0.63 ± 7.19 0.46 ± 0.82
Clinically inactive MS patients 35 10/25 39.5 ± 11.5 1.50 ± 0.63 7.00 ± 9.25 16.87 ± 34.43
Progressive MS patients 35 12/23 52.0 ± 15.0 4.50 ± 2.50 17.0 ± 12.0
Healthy control subjects 45 21/24 34.0 ± 28.5
  1. MS multiple sclerosis, EDSS expanded disability status scale
  2. aMedian ± interquartile range